查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2003052

生物製藥合約開發和生產組織 (CDMO) 市場：2026-2032 年全球市場預測（按服務類型、表現系統、治療領域、開發階段和最終用戶分類）

Biologics Contract Development & Manufacturing Organization Market by Service Type, Expression System, Therapeutic Category, Development Phase, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年生技藥品合約開發和生產 (CDMO) 市場價值為 114 億美元，預計到 2026 年將成長至 122.6 億美元，複合年成長率為 7.71%，到 2032 年將達到 191.8 億美元。

主要市場統計數據
基準年 2025 114億美元
預計年份：2026年 122.6億美元
預測年份 2032 191.8億美元
複合年成長率 (%) 7.71%

一篇精闢而富有洞察力的介紹文章重點闡述了技術、監管和商業性因素如何重塑生物製藥 CDMO夥伴關係和業務重點。

生物製藥合約開發與生產（CDMO）產業正經歷一場策略重組，其驅動力來自技術進步、日益嚴格的監管要求以及日益激烈的競爭格局。各種規模的機構都在重新評估與外部生產商從藥物發現到商業化的合作方式，同時應對供應鏈脆弱性和人才短缺等挑戰。先進的表達系統、不斷發展的治療方法以及研發人員的營運需求相互作用，共同塑造了品質、速度和柔軟性的新標準。現有企業必須滿足這些標準才能保持競爭力。

快速的技術進步、策略性合併以及贊助商期望的變化如何創造生物製藥製造領域新的競爭格局和夥伴關係模式。

隨著申辦方和服務供應商諸如快速過渡到臨床試驗、更嚴格的監管審查以及為支持多樣化治療方法而需要靈活的生產能力等新挑戰，生物製藥生產生態系統正經歷著變革性的變化。表達系統和下游製程的進步提高了產量和產品均一性，而分析技術和數位化過程監控的同步發展則提高了人們對可追溯性和品質保證的期望。這些技術變革與策略轉變相輔相成，越來越多的申辦者從簡單的外包轉向包含共同開發和風險共擔安排的策略夥伴關係。

了解預期中的貿易政策變化和關稅調整將如何重塑生物製藥開發和製造中的採購、產能分配和供應商策略。

預計2025年的關稅變化和貿易政策調整將為生物製藥供應鏈、籌資策略和跨境生產夥伴關係帶來一系列複雜的考量。關稅可能對關鍵原料、一次性耗材以及填充、精加工和包裝流程中特定組件的到貨成本產生重大影響，迫使企業重新評估其採購區域和合約條款。為此，贊助商和契約製造可能會加快供應商多元化，建立區域採購中心，並重新談判長期供應契約，以減輕潛在的成本波動並維持生產計劃。

基於細分的洞察揭示了服務類型、表達平台、治療領域、開發階段需求和最終用戶概況如何決定 CDMO 的能力和策略重點。

從精細的市場區隔觀點，不同服務類型、表達系統、治療領域、研發階段和最終用戶的需求促進因素、營運要求和價值提案有顯著差異。基於服務類型，市場可區分藥品製劑服務及原料原料藥服務，二者均需特定的技術能力及監管流程，因此合作夥伴的選擇標準也各不相同。基於表達系統，供應商和申辦者需權衡哺乳動物細胞平台和微生物平台之間的優劣。對於含有複雜聚醣的蛋白質，哺乳動物細胞系統需要對Cho、Hek和Ns0細胞株擁有深厚的專業知識；而大腸桿菌和酵母等微生物方法則擅長快速、經濟高效地生產結構相對簡單的分子。

區域趨勢分析顯示了美洲、歐洲、中東和非洲以及亞太地區生物製藥製造的獨特優勢和戰略考量。

區域趨勢持續影響全球生物製藥產業的投資決策、企業發展和夥伴關係策略。美洲的優勢包括完善的法規結構、充足的設施擴建資金以及眾多需要大規模哺乳動物細胞生產能力的贊助商。該地區通常優先考慮與國內臨床開發項目整合，並透過本地能力建設來增強供應鏈的韌性。歐洲、中東和非洲（EMEA）則呈現出多元化的環境，監管協調的努力與區域專業知識並存，從而能夠提供從利基市場到商業規模的高品質契約製造服務，並促進各國領先研究中心之間的合作。

大型和利基服務供應商的企業策略和能力建設趨勢正在推動生物製藥製造領域的競爭差異化和長期韌性。

在生物製藥合約開發與生產（CDMO）領域，主要企業和創新型新參與企業正採取差異化策略，以確保穩定的收入來源和技術領先地位。許多成熟的供應商正在擴展其端到端能力，以期在從原料藥到成品的整個工作流程中創造價值，並投資於模組化設施和一次性平台，以提高產能柔軟性，同時降低初始投資的資本密集度。同時，一些公司專注於高級分析、高活性藥物生產或基因和細胞療法供應鏈等專業細分領域，力求在深厚的科學專業知識成為決定性競爭優勢的領域佔據高階地位。

在生物製藥 CDMO 業務中，高階主管和營運經理可以實施實際有效的措施來提高柔軟性、降低執行風險並增強競爭優勢。

在快速發展的生物製藥製造生態系統中，產業領導企業可以採取果斷措施，保持敏捷性、控制風險並抓住成長機會。首先，優先投資於支援多種表達系統和可擴展下游製程的靈活平台，以適應不斷變化的客戶需求和治療模式。這種柔軟性可以減輕重新驗證的負擔，並縮短技術轉移週期。其次，透過包含明確管治和應急條款的多年戰略契約，加強與供應商的關係，以應對貿易政策和原料供應的波動。第三，加快數位化製程控制和先進分析技術，以提高產量、減少批次缺陷，並向監管機構證明卓越的資料完整性。

我們採用透明嚴謹的調查方法，結合專家訪談、文件審查和資料三角驗證，為生物製藥製造領域的相關人員提供檢驗且可操作的見解。

支持這些洞見的研究是透過一套系統性的調查方法進行的，該方法結合了有針對性的初步研究和嚴謹的二級資訊來源檢驗。初步研究包括對眾多贊助商和服務供應商的技術領導者、監管事務專家和銷售主管進行深入訪談，從而能夠深入了解營運限制和客戶決策標準。二手研究系統地考察了監管指南、專利趨勢、技術白皮書和公開的企業資訊披露，將初步研究的結果置於特定背景下，以識別行業中的潛在模式。

簡潔的結論強調了在不斷發展的生物製藥 CDMO 生態系統中取得成功所必需的策略轉變、必要投資和協作方法。

總之，生物製藥合約開發與生產（CDMO）產業正受到技術創新、客戶偏好變化以及日益複雜的地緣政治和法規環境的重塑。這些因素正推動產業向更具策略性和一體化的夥伴關係轉變，迫使服務供應商投資於靈活的平台、先進的分析能力和完善的品質系統。同時，客戶也在尋求能夠提供安全且多元化供應鏈的合作夥伴，以平衡速度和監管嚴格性，從而支持快速開發和長期商業化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製藥合約開發與生產組織（CDMO）市場：依服務類型分類

  • 配方
  • 原料藥

第9章：生物製藥合約開發和生產組織（CDMO）市場表現系統（按系統分類）

  • 哺乳動物
    • 趙
    • HEK
    • Ns0
  • 微生物
    • 大腸桿菌
    • 酵母菌

第10章：按治療領域分類的生物製藥合約開發和生產組織（CDMO）市場

  • 免疫學
  • 感染疾病
  • 神經病學
  • 腫瘤學

第11章：生物製藥合約開發與生產組織（CDMO）市場依開發階段分類

  • 商業的
  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前

第12章：生物製藥合約開發與生產組織（CDMO）市場：依最終用戶分類

  • 生技公司/中小型醫療保健公司
  • 合約研究機構
  • 大型製藥企業

第13章：生物製藥合約開發與生產組織（CDMO）市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生物製藥合約開發與生產組織（CDMO）市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物製藥合約開發與生產組織（CDMO）市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物製藥合約開發與生產組織（CDMO）市場

第17章：中國生物製藥合約研發生產機構（CDMO）市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JSR Life Sciences, LLC
  • Jubilant Biosys Limited
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Tegra Medical
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc
Product Code: MRR-957C47F9527F

The Biologics Contract Development & Manufacturing Organization Market was valued at USD 11.40 billion in 2025 and is projected to grow to USD 12.26 billion in 2026, with a CAGR of 7.71%, reaching USD 19.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.40 billion
Estimated Year [2026] USD 12.26 billion
Forecast Year [2032] USD 19.18 billion
CAGR (%) 7.71%

An incisive introduction highlighting how technological, regulatory, and commercial forces are reshaping biologics CDMO partnerships and operational priorities

The biologics contract development and manufacturing landscape is entering a period of strategic recalibration driven by technological advancement, heightened regulatory expectations, and intensified competitive dynamics. Organizations of all sizes are reassessing how they partner with external manufacturers to bring complex molecules from discovery through commercialization, while simultaneously navigating supply chain fragility and workforce constraints. The interplay between advanced expression systems, evolving therapeutic modalities, and the operational needs of developers has created new benchmarks for quality, speed, and flexibility that incumbent players must meet to remain relevant.

Against this backdrop, industry stakeholders increasingly prioritize end-to-end partnerships that deliver technical depth alongside commercial agility. Innovative service models, including integrated drug substance and drug product capabilities, are redefining customer expectations and enabling faster transitions across development phases. Furthermore, investments in single-use technologies, modular facilities, and digital process controls are not merely cost-management tactics but strategic enablers that support both scalability and regulatory compliance. Taken together, these forces are reshaping how sponsors select partners, structure contracts, and plan long-term supply strategies, setting the stage for a more resilient and innovation-driven market environment.

How rapid technological advances, strategic consolidation, and shifting sponsor expectations are creating new competitive dynamics and partnership models in biologics manufacturing

The biologics manufacturing ecosystem is experiencing transformative shifts as sponsors and service providers adapt to a new set of imperatives: faster time-to-clinic, higher regulatory scrutiny, and the need for flexible manufacturing capacity that supports diverse modalities. Advances in expression systems and downstream processing are enabling higher yields and greater product consistency, while parallel developments in analytics and digital process monitoring are elevating expectations for traceability and quality assurance. These technological shifts are complemented by strategic shifts: more sponsors are moving from transactional outsourcing to strategic alliances that embed co-development and risk-sharing arrangements.

Concurrently, market dynamics are driving consolidation and specialization. Large-scale strategic investments are being directed toward capacity that supports mammalian cell expression for complex monoclonal antibodies and cell therapy supply chains, while niche providers are differentiating through microbial systems optimized for rapid recombinant protein production. This divergence is prompting sponsors to adopt hybrid sourcing strategies that pair flexible, small-scale capacity for early-stage development with robust commercial-scale partners for later-stage manufacturing. As a result, long-term supplier relationships, investment in platform technologies, and the ability to pivot between expression systems and development phases are becoming core determinants of competitive advantage. Policymakers and regulators are also influencing these shifts by emphasizing supply chain transparency and quality metrics, which further shapes capital allocation and operational design across the sector.

Understanding how projected trade policy shifts and tariff adjustments could reshape sourcing, capacity allocation, and supplier strategies across biologics development and manufacturing

Anticipated tariff changes and trade policy adjustments in 2025 present a complex set of considerations for biologics supply chains, procurement strategies, and cross-border manufacturing partnerships. Tariffs can materially influence the landed cost of critical raw materials, single-use consumables, and certain components of fill-finish and packaging operations, leading organizations to reassess sourcing geographies and contractual terms. In response, sponsors and contract manufacturers may accelerate supplier diversification, establish regional sourcing hubs, or renegotiate long-term supply agreements to mitigate potential cost volatility and preserve production timelines.

Beyond direct input costs, tariff-driven shifts can have second-order effects on project planning and capacity allocation. For example, higher import duties on certain equipment or consumables could incentivize onshoring of specific manufacturing steps, particularly those with specialized regulatory oversight or cold-chain dependencies. Such moves would alter capital deployment decisions and may prioritize investments in modular, relocatable assets that reduce exposure to cross-border tariff risk. Additionally, logistics complexity may rise as firms seek to avoid tariff exposure through multi-leg routing or localized warehousing, which in turn creates operational friction and potential delays. Importantly, regulatory compliance remains non-negotiable; any adjustments to sourcing or manufacturing location must account for validation requirements and supply chain transparency obligations to avoid downstream approval setbacks. Overall, prudent scenario planning, flexible contract terms, and strengthened supplier relationships will be essential tools for mitigating the cumulative impacts of trade policy shifts on biologics development and commercialization.

Segmentation-driven insights revealing how service types, expression platforms, therapeutic focus, development phase needs, and end-user profiles dictate CDMO capabilities and strategic priorities

A nuanced segmentation lens reveals meaningful differences in demand drivers, operational requirements, and value propositions across service types, expression systems, therapeutic categories, development phases, and end users. Based on service type, the market distinguishes between drug product and drug substance services, each demanding specific technical capabilities and regulatory processes and prompting different partner selection criteria. Based on expression system, providers and sponsors evaluate trade-offs between mammalian and microbial platforms; mammalian systems require deep expertise in Cho, Hek, and Ns0 cell lines for complex glycosylated proteins, while microbial approaches such as E coli and yeast excel at rapid, cost-effective production for less complex molecules.

Based on therapeutic category, customer requirements vary significantly across immunology, infectious disease, neurology, and oncology, with oncology often necessitating highly tailored development pathways and immunology prioritizing robust scale-up capability. Based on development phase, needs evolve from preclinical and Phase I, where speed and flexibility are paramount, through Phase II and Phase III, where process robustness and scalable supply chain architectures become critical, to commercial stage where long-term capacity commitments, regulatory stability, and cost efficiency dominate decision criteria. Based on end user, expectations differ between biotech small and medium enterprises, contract research organizations, and large pharmaceutical firms; smaller biotech clients often prioritize agility and deep technical partnership, while large pharma typically seeks integrated global networks and stringent compliance systems. Together, these segmentation dimensions define the contours of demand and inform where investments in capability, quality systems, and commercial models will deliver the greatest strategic value.

Regional landscape analysis showing how the Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct advantages and strategic considerations for biologics manufacturing

Regional dynamics continue to shape investment decisions, operational footprints, and partnership strategies across the global biologics manufacturing landscape. In the Americas, strengths include established regulatory frameworks, deep capital pools for facility expansion, and a concentration of sponsors requiring large-scale mammalian manufacturing capacity; this region often emphasizes integration with domestic clinical development programs and prioritizes supply chain resilience through localized capabilities. Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with regional specialization, enabling a mix of high-quality contract services for both niche and commercial-scale programs and fostering collaboration across national centers of excellence.

Asia-Pacific is distinguished by rapid capacity growth, competitive cost structures, and an expanding pool of technical talent, making it an important hub for both early-stage development work and commercial manufacturing for export-oriented clients. However, cross-border regulatory alignment and technology transfer considerations remain important when leveraging regional capacity. Across all regions, stakeholders increasingly factor in geopolitical dynamics, logistics complexity, and the availability of skilled workforce when making siting and partnership decisions. Strategic regional diversification, coupled with adherence to global quality standards and proactive regulatory planning, helps sponsors manage operational risk while accessing the advantages each region offers for different phases of product development and commercialization.

Corporate strategies and capability-building trends among major and niche service providers that are driving competitive differentiation and long-term resilience in biologics manufacturing

Leading companies and innovative entrants are pursuing differentiated strategies to secure resilient revenue streams and technological leadership in biologics contract development and manufacturing. Many incumbent providers are expanding end-to-end capabilities to capture value across drug substance and drug product workflows, investing in modular facilities and single-use platforms to increase throughput flexibility while lowering up-front capital intensity. Others are focusing on specialized niches, such as advanced analytics, high-potency manufacturing, or gene and cell therapy supply chains, to command premium positioning where deep scientific expertise is a decisive competitive moat.

Strategic partnerships and alliance models are increasingly prominent, with sponsors seeking collaborators that can co-invest in platform development or capacity expansions. Digitalization and automation investments are being leveraged not only to increase operational efficiency but also to enhance data integrity, regulatory readiness, and remote process monitoring-capabilities that are especially attractive to global pharmaceutical clients. Talent and knowledge management remain critical differentiators; firms that combine robust training programs with cross-functional scientific teams are better positioned to support complex transfer projects and accelerated timelines. Finally, environmental, social, and governance priorities are becoming integral to corporate strategies, with sustainability initiatives increasingly influencing customer selection and long-term contractual negotiations.

Practical, high-impact actions that senior executives and operational leaders can implement to improve flexibility, reduce execution risk, and strengthen competitive positioning in biologics CDMO operations

Industry leaders can take decisive steps to preserve agility, manage risk, and capture growth opportunities in a rapidly evolving biologics manufacturing ecosystem. First, prioritize flexible platform investments that support multiple expression systems and scalable downstream processing to accommodate shifting client mixes and therapeutic modalities; such flexibility reduces revalidation burdens and shortens technology transfer timelines. Second, strengthen supplier relationships through multi-year strategic agreements with clear governance and contingency clauses that address trade policy volatility and raw material availability. Third, accelerate adoption of digital process control and advanced analytics to improve yield, reduce batch failures, and demonstrate superior data integrity to regulators.

In addition, diversify regional capacity strategically rather than uniformly, aligning facility types to regional advantages-early-phase development hubs in regions offering rapid turnaround and commercial-scale production in regions with proven regulatory alignment. Invest in workforce development and cross-training programs to mitigate talent bottlenecks and ensure continuity during scale-up or transfer activities. Finally, incorporate sustainability and ESG metrics into operational planning to meet emerging customer expectations and regulatory disclosure trends; this includes evaluating circular supply chain opportunities for single-use systems and reducing energy and water footprints where feasible. By implementing these measures, leaders can reduce execution risk, improve customer retention, and position their organizations for sustained competitiveness in a dynamic market.

A transparent and rigorous research methodology combining expert interviews, documentation review, and data triangulation to produce validated actionable insights for biologics manufacturing stakeholders

The research underpinning these insights was developed through a structured methodology that combined targeted primary engagement with subject-matter experts and rigorous secondary-source validation. Primary research included in-depth interviews with technical leaders, regulatory affairs professionals, and commercial executives across a spectrum of sponsors and service providers, enabling nuanced understanding of operational constraints and customer decision criteria. Secondary research involved a systematic review of regulatory guidance, patent landscapes, technology white papers, and publicly available company disclosures to contextualize primary findings and identify persistent industry patterns.

Data triangulation was applied throughout to reconcile divergent perspectives and validate conclusions, with special attention given to cross-referencing interview findings against facility filings, regulatory approvals, and equipment vendor capabilities. Segmentation mapping was employed to align capability indicators with service types, expression systems, therapeutic categories, development phases, and end-user profiles, ensuring that recommendations were grounded in empirically observed behaviors. Finally, limitations and potential biases were explicitly considered, including geographic sampling constraints and respondent confidentiality concerns, and were mitigated through methodological transparency and iterative validation with independent experts.

A concise conclusion emphasizing the strategic shifts, imperative investments, and collaborative approaches needed to thrive in the evolving biologics CDMO ecosystem

In conclusion, the biologics contract development and manufacturing sector is being reshaped by technological innovation, evolving sponsor preferences, and an increasingly complex geopolitical and regulatory environment. These forces are driving a shift toward more strategic, integrated partnerships and compelling service providers to invest in flexible platforms, enhanced analytics, and robust quality systems. Sponsors, in turn, are seeking partners that can balance speed with regulatory rigor and provide secure, diversified supply chains capable of supporting both rapid development and long-term commercialization.

Looking forward, organizations that proactively address tariff-driven supply risks, align regional investments with strategic therapeutic priorities, and adopt digital and sustainability-focused practices will be better positioned to meet the demands of next-generation biologics programs. Collaboration across the ecosystem-between technology vendors, contract providers, and sponsors-will be critical to accelerate capability development and to ensure that operational changes translate into reliable patient access. The collective ability to manage complexity while maintaining regulatory compliance and scientific excellence will determine which organizations emerge as preferred long-term partners in the biologics era.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Development & Manufacturing Organization Market, by Service Type

  • 8.1. Drug Product
  • 8.2. Drug Substance

9. Biologics Contract Development & Manufacturing Organization Market, by Expression System

  • 9.1. Mammalian
    • 9.1.1. Cho
    • 9.1.2. Hek
    • 9.1.3. Ns0
  • 9.2. Microbial
    • 9.2.1. E Coli
    • 9.2.2. Yeast

10. Biologics Contract Development & Manufacturing Organization Market, by Therapeutic Category

  • 10.1. Immunology
  • 10.2. Infectious Disease
  • 10.3. Neurology
  • 10.4. Oncology

11. Biologics Contract Development & Manufacturing Organization Market, by Development Phase

  • 11.1. Commercial
  • 11.2. Phase I
  • 11.3. Phase Ii
  • 11.4. Phase Iii
  • 11.5. Preclinical

12. Biologics Contract Development & Manufacturing Organization Market, by End User

  • 12.1. Biotech Small Med
  • 12.2. Contract Research Org
  • 12.3. Large Pharma

13. Biologics Contract Development & Manufacturing Organization Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biologics Contract Development & Manufacturing Organization Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biologics Contract Development & Manufacturing Organization Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biologics Contract Development & Manufacturing Organization Market

17. China Biologics Contract Development & Manufacturing Organization Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie, Inc.
  • 18.6. Abzena Ltd.
  • 18.7. Aenova Holding GmbH
  • 18.8. AGC Biologics GmbH
  • 18.9. Avid Bioservices, Inc.
  • 18.10. Binex Co. Limited
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Cambrex Corporation
  • 18.13. Catalent, Inc.
  • 18.14. Emergent BioSolutions, Inc.
  • 18.15. Fujifilm Holdings Corporation
  • 18.16. Icon PLC
  • 18.17. JSR Life Sciences, LLC
  • 18.18. Jubilant Biosys Limited
  • 18.19. Lonza Group AG
  • 18.20. Parexel International Corporation
  • 18.21. ProBioGen AG
  • 18.22. Recipharm AB
  • 18.23. Rentschler Biopharma SE
  • 18.24. Samsung Biologics
  • 18.25. Takeda Pharmaceutical Company Limited
  • 18.26. Tegra Medical
  • 18.27. Thermo Fisher Scientific, Inc.
  • 18.28. Toyobo Co., Ltd.
  • 18.29. WuXi Biologics Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 183. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)